| Expression pattern: |
UP |
| Associated gene: |
TFII-I, STAT1, CXCL10, CXCL11 |
| Associated microRNA: |
- |
| Biological function: |
Inhibits CD8+ T cell infiltration/chemotaxis by suppressing CXCL10 and CXCL11 expression; promotes tumor progression and attenuates anti-PD-1 efficacy in vivo. |
| Molecular mechanism: |
circFNDC3B binds TFII-I, competitively disrupts TFII-I/STAT1 complex formation, reduces STAT1 phosphorylation and transcriptional activation of CXCL10/CXCL11, impairing chemokine-dependent CD8+ T cell recruitment. |
| Biological pathway or process: |
immune regulation (inhibits); other pathway/process (inhibits) |
| Detected method: |
Q
S
|
| Validation methods: |
circRNA-seq; RNase R Treatment; RT-qPCR; Clinical Sample Validation; Survival Analysis; Back-Splice Junction PCR / divergent primers PCR; Sanger Sequencing; Actinomycin D / DRB Stability Assay; Nuclear-Cytoplasmic Fractionation; FISH / smFISH; RNA Pull-Down; RIP (RNA Immunoprecipitation); Western Blot; Co-IP; ChIP / ChIP-seq; Luciferase Reporter Assay; Transfection; ELISA; Transwell Assay; In Vivo Animal Model; IHC (Immunohistochemistry); IF (Immunofluorescence); Flow Cytometry（Non-apoptosis/cycle） |
| Clinical significance: |
High circFNDC3B expression was associated with worse overall survival (OS) in NSCLC patients. |
| Description: |
circFNDC3B is up-regulated in NSCLC and mainly nuclear in tumor cells. It binds TFII-I and disrupts TFII-I/STAT1 transcriptional complex formation, suppressing CXCL10/CXCL11 expression and thereby limiting CD8+ T-cell recruitment and anti-tumor immunity; high circFNDC3B associates with worse OS. |
| Confidence score: |
0.8907 |